Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04083378 · OUTCOME

Extrahepatic Progression-free Survival

Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study · Source last updated 2026-03-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Up to 2 years

What was measured

Competing risk analysis was conducted to estimate the 2-year extrahepatic cumulative incidence of progression, considering the progression of the ablated tumor and treating death as a competing event.

Analysis population: The 2-year secondary endpoints are provided in this analysis

Groups in this outcome

Experimental

Clinical impact of Morfeus software usage on patients undergoing percutaneous thermal ablation of liver tumors

Control

Morfeus software was not used during percutaneous ablation of hepatic mets

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Experimental74
Control26

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Experimental34.5Not reported24.847.8Not reported
Control41.4Not reported25.467.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        24.8
        upper Limit
        47.8
        value
        34.5
      2. group Id
        OG001
        lower Limit
        25.4
        upper Limit
        67.3
        value
        41.4
denoms
  1. counts
    1. group Id
      OG000
      value
      74
    2. group Id
      OG001
      value
      26
    units
    Participants
description
Competing risk analysis was conducted to estimate the 2-year extrahepatic cumulative incidence of progression, considering the progression of the ablated tumor and treating death as a competing event.
dispersion Type
95% Confidence Interval
groups
  1. description
    Clinical impact of Morfeus software usage on patients undergoing percutaneous thermal ablation of liver tumors
    id
    OG000
    title
    Experimental
  2. description
    Morfeus software was not used during percutaneous ablation of hepatic mets
    id
    OG001
    title
    Control
param Type
NUMBER
population Description
The 2-year secondary endpoints are provided in this analysis
reporting Status
POSTED
time Frame
Up to 2 years
title
Extrahepatic Progression-free Survival
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice